16077-78-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Thiazol-2-yl-propan-2-ol is used as a building block for the synthesis of various pharmaceutical products due to its antimicrobial, antifungal, and antiviral activities. It plays a crucial role in the development of new drugs and treatments for various diseases.
Used in Agrochemical Industry:
2-Thiazol-2-yl-propan-2-ol is used as a building block in the synthesis of agrochemical products, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Chemical Industry:
2-Thiazol-2-yl-propan-2-ol is used as an intermediate in the production of rubber accelerators, dyes, and other organic compounds, enhancing the properties and performance of these materials.
Used in Research and Development:
2-Thiazol-2-yl-propan-2-ol is utilized in research and development for the exploration of its potential applications in various fields, including drug discovery, material science, and chemical synthesis. Its unique properties and low toxicity make it an attractive candidate for further investigation and application.

InChI:InChI=1/C6H9NOS/c1-6(2,8)5-7-3-4-9-5/h3-4,8H,1-2H3

Upstream product

• 288-47-1 1,3-thiazole 
• 67-64-1 acetone 
• 3034-53-5 2-bromo-1,3-thiazole 
• 24295-03-2 2-Acetylthiazole 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 362719-46-8 4-{2-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]-2-[5-(2-(1-methyl-1-[(2-trimethylsilylethoxy)methoxy]ethyl)thiazolyl)]ethyl}pyridine N-oxide 
• 362719-42-4 (+/-)-[(3-cyclobutyloxy-4-difluoromethoxy)phenyl]{2-[1-methyl-1-(2-trimethylsilylethoxy)methoxy]ethylthiazol-5-yl}methanol 
• 1026236-19-0 5-[chloro-(3-cyclobutoxy-4-difluoromethoxy-phenyl)-methyl]-2-[1-methyl-1-(2-trimethylsilanyl-ethoxymethoxy)-ethyl]-thiazole 

Relevant academic research and scientific papers

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Dihydroisoquinoline compound

The invention provides a dihydroisoquinoline compound or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug or isotope marker thereof. The compound has a structure shown as ageneral formula I. The compound has extremely strong activity of inhibiting hepatitis B surface antigen, also has extremely strong activity of inhibiting hepatitis B DNA, has relatively high bioavailability, can play a drug effect at a relatively low dosage, and reduces the potential toxicity of the compound.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R 2 R 3, R 4 and R are as defined herein. The present i

THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present

IMIDAZOPYRAZINE SYK INHIBITORS

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suf-fering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or dis-order are provided.

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Alkyne-aryl phosphodiesterase-4 inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

Tri-aryl-substituted-ethane PDE4 inhibitors

Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.